EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

BCG therapy in bladder cancer and its tumor microenvironment interactions

Ni Jian iD, Lei Yu, Lijuan Ma, Binbin Zheng iD, Weiren Huang iD

Clinical Microbiology Reviews · 12.06.2025 · 38 (2)

DOI: 10.1128/cmr.00212-24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 12.06.2025. Verfasst von Ni Jian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Synthetic Biology Research Center, Institute for Advanced Study, International Cancer Center of Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Tumor Microenvironment, BCG Vaccine, Mycobacterium bovis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 304 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Key R&D Program of China, the Shenzhen Institute of Synthetic Biology Scientific Research Program, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacillus Calmette-Guérin (BCG) has been the standard treatment for non-muscle-invasive bladder cancer for over 30 years. Despite its proven efficacy, challenges persist, including unclear mechanisms of action, resistance in 30%–50% of patients, and significant side effects. This review presents an updated and balanced discussion of the antitumor mechanisms of BCG, focusing on its direct effects on bladder cancer and its interactions with various cell types within the bladder tumor microenvironment. Notably, recent research on the interactions between BCG and the bladder microbiome is also incorporated. We further summarize and analyze the latest preclinical and clinical studies regarding both intrinsic and adaptive resistance to BCG in bladder cancer. Based on the current understanding of BCG’s therapeutic principles and resistance mechanisms, we systematically explore strategies to improve BCG-based tumor immunotherapy. These include the development of recombinant BCG, combination therapy with different drugs, optimization of therapeutic regimens and management, and the exploration of new approaches by targeting changes in the bladder microbiota and its metabolites. These measures aim to effectively address the BCG resistance in bladder cancer, reduce its toxicity, and ultimately enhance the clinical anti-tumor efficacy. Bacterial therapy, represented by genetically engineered oncolytic bacteria, has gradually emerged in the field of cancer treatment in recent years. As the only bacterial drug successfully approved for oncology use, BCG has provided decades of clinical experience. By consolidating lessons from BCG’s successes and limitations, we hope to provide valuable insights for the development and application of bacterial therapies in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsTumor MicroenvironmentBCG VaccineMycobacterium bovisHumansImmunotherapyAnimals

Stichwörter der Autor:innen

Bacillus Calmette-Guérinbacterial therapybladder cancerdrug resistanceimmunotherapymicrobiometumor microenvironment

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Synthetic Biology Research Center, Institute for Advanced Study, International Cancer Center of Shenzhen University, Shenzhen, China.
  • School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, China.
  • Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy Faculty of Medicine, Macau University of Science and Technology, Macau, China.
  • College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China.

ORCID-Profile: Ni Jian, Binbin Zheng, Weiren Huang

Förderung

  • the National Key R&D Program of China
  • the Shenzhen Institute of Synthetic Biology Scientific Research Program
  • the National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • GDSTC | Guangdong Special Support Plan
  • the Shenzhen Portion of Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone
  • the Shenzhen Medical Research Fund
  • the Shenzhen Municipal Government of China

Zitieren

APA

Jian, N., Yu, L., Ma, L., Zheng, B., & Huang, W. (2025). BCG therapy in bladder cancer and its tumor microenvironment interactions. Clinical Microbiology Reviews, 38(2). https://doi.org/10.1128/cmr.00212-24

Vancouver

Jian N, Yu L, Ma L, Zheng B, Huang W. BCG therapy in bladder cancer and its tumor microenvironment interactions. Clinical Microbiology Reviews. 2025;38(2). doi:10.1128/cmr.00212-24

BibTeX
@article{Jian2025,
  author = {Jian, Ni and Yu, Lei and Ma, Lijuan and Zheng, Binbin and Huang, Weiren},
  title = {BCG therapy in bladder cancer and its tumor microenvironment interactions},
  journal = {Clinical Microbiology Reviews},
  year = {2025},
  volume = {38},
  number = {2},
  doi = {10.1128/cmr.00212-24}
}
Kostenlos starten →